Rémy Villeneuve

Dr. Rémy Villeneuve

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
OROlivier Riou
Olivier Riou
BSBenjamin Serrano
Benjamin Serrano
david azriadavid azria
david azria
BPBenoit Paulmier
Benoit Paulmier
RVRémy Villeneuve
Rémy Villeneuve
Juliette THARIATJuliette THARIAT
Juliette THARIAT
To assess the feasibility and benefit of integrating four-dimensional (4D) Positron Emission Tomography (PET) – computed tomography (CT) for liver stereotactic body radiation therapy (SBRT) planning. 8 patients with 14 metastases were accrued in the study. They all underwent a non-gated PET and a 4D PET centered on the liver. The same CT scan was used for attenuation correction, registration, and considered the planning CT for SBRT planning. Six PET phases were reconstructed for each 4D PET. By applying an individualized threshold to the 4D PET, a Biological Internal Target Volume (BITV) was generated for each lesion. A gated Planning Target Volume (PTVg) was created by adding 3 mm to account for set-up margins. This volume was compared to a manual Planning Target Volume (PTV) delineated with the help of a semi-automatic Biological Target Volume (BTV) obtained from the non-gated exam. A 5 mm radial and a 10 mm craniocaudal margins were applied to account for tumor motion and set-up margins to create the PTV. One undiagnosed liver metastasis was discovered thanks to the 4D PET. The semi-automatic BTV were significantly smaller than the BITV (p = 0.0031). However, after applying adapted margins, 4D PET allowed a statistically significant decrease in the PTVg as compared to the PTV (p = 0.0052). In comparison to non-gated PET, 4D PET may better define the respiratory movements of liver targets and improve SBRT planning for liver metastases. Furthermore, non respiratory-gated PET exams can both misdiagnose liver metastases and underestimate the real internal target volumes.

1 February 1996 in Czechoslovak Journal of Physics
Verified
Journal Article
Closed access
PDF file
PBP. Bourges
P. Bourges
YSY. Sidis
Y. Sidis
BHB. Hennion
B. Hennion
RVRémy Villeneuve
Rémy Villeneuve
JMJ. F. Marucco
J. F. Marucco
GCG. Collin
G. Collin

7 December 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
WEWilliam Echavidre
William Echavidre
JDJerome Durivault
Jerome Durivault
CGCélia Gotorbe
Célia Gotorbe
TBThays Blanchard
Thays Blanchard
MPMarina Pagnuzzi
Marina Pagnuzzi
Christopher MontemagnoChristopher Montemagno
Christopher Montemagno
Medulloblastoma is one of the most prevalent solid tumors found in children, occurring in the brain's posterior fossa. The standard treatment protocol involves maximal resection surgery followed by craniospinal irradiation and chemotherapy. Despite a long-term survival rate of 70%, wide disparities among patients have been observed. The identification of pertinent targets for both initial and recurrent medulloblastoma cases is imperative. Both primary and recurrent medulloblastoma are marked by their aggressive infiltration into surrounding brain tissue, robust angiogenesis, and resistance to radiotherapy. While the significant role of integrin-αvβ3 in driving these characteristics has been extensively documented in glioblastoma, its impact in the context of medulloblastoma remains largely unexplored. Integrin-αvβ3 was found to be expressed in a subset of patients with medulloblastoma. We investigated the role of integrin-αvβ3 using medulloblastoma-derived cell lines with β3-subunit depletion or overexpression both in vitro and in vivo settings. By generating radioresistant medulloblastoma cell lines, we uncovered an increased integrin-αvβ3 expression, which correlated with increased susceptibility to pharmacologic integrin-αvβ3 inhibition with cilengitide, a competitive ligand mimetic. Finally, we conducted single-photon emission computed tomography (SPECT)/MRI studies on orthotopic models using a radiolabeled integrin-αvβ3 ligand (99mTc-RAFT-RGD). This innovative approach presents the potential for a novel predictive imaging technique in the realm of medulloblastoma. Altogether, our findings lay the foundation for employing SPECT/MRI to identify a specific subset of patients with medulloblastoma eligible for integrin-αvβ3–directed therapies. This breakthrough offers a pathway toward more targeted and effective interventions in the treatment of medulloblastoma. Significance: This study demonstrates integrin-αvβ3’s fundamental role in medulloblastoma tumorigenicity and radioresistance and the effect of its expression on cilengitide functional activity.

20 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
CGCélia Gotorbe
Célia Gotorbe
FSFabien Segui
Fabien Segui
WEWilliam Echavidre
William Echavidre
JDJerome Durivault
Jerome Durivault
TBThays Blanchard
Thays Blanchard
Christopher MontemagnoChristopher Montemagno
Christopher Montemagno
Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death induced by ROS and inhibited by antioxidants such as cysteine, glutathione (GSH), and glutathione peroxidase 4 (GPx4). However, the link between αvβ3 expression, ferroptosis inhibition, and sensitivity to radiotherapy remains unclear. We showed that irradiated β3_KO medulloblastoma cells primarily die by ferroptosis, with β3-subunit expression correlating with radiotherapy sensitivity and anti-ferroptotic protein levels. Our findings suggest that integrin-αvβ3 signaling boosts oxidative stress resilience via mTORC1. Thus, targeting integrin-αvβ3 could enhance radiotherapy efficacy in medulloblastoma by inducing ferroptotic cell death.

1 February 2020
Verified
Conference Paper
Closed access
FAFarid Elyamani Arwa
Farid Elyamani Arwa
CMCueille Marylene
Cueille Marylene
CACastagnetti Andrea
Castagnetti Andrea
PPPeyrard Philippe
Peyrard Philippe
RVRémy Villeneuve
Rémy Villeneuve
DJDubard Jean-Lou
Dubard Jean-Lou
In this article, we present a dosimetry study on the evaluation of SAR 10g depending on the antenna’s position, morphology and biological tissues. The device under consideration is a new innovative connected glasses developed by the Ellcie-Healthy startup. Realistic modelling using heterogeneous human voxels are performed to obtain reliable results. The simulated SAR values remain below the current exposure limits.

7 December 2023
Verified
Other
Open access
WEWilliam Echavidre
William Echavidre
JDJerome Durivault
Jerome Durivault
CGCélia Gotorbe
Célia Gotorbe
TBThays Blanchard
Thays Blanchard
MPMarina Pagnuzzi
Marina Pagnuzzi
Christopher MontemagnoChristopher Montemagno
Christopher Montemagno
Medulloblastoma is one of the most prevalent solid tumors found in children, occurring in the brain's posterior fossa. The standard treatment protocol involves maximal resection surgery followed by craniospinal irradiation and chemotherapy. Despite a long-term survival rate of 70%, wide disparities among patients have been observed. The identification of pertinent targets for both initial and recurrent medulloblastoma cases is imperative. Both primary and recurrent medulloblastoma are marked by their aggressive infiltration into surrounding brain tissue, robust angiogenesis, and resistance to radiotherapy. While the significant role of integrin-αvβ3 in driving these characteristics has been extensively documented in glioblastoma, its impact in the context of medulloblastoma remains largely unexplored. Integrin-αvβ3 was found to be expressed in a subset of patients with medulloblastoma. We investigated the role of integrin-αvβ3 using medulloblastoma-derived cell lines with β3-subunit depletion or overexpression both in vitro and in vivo settings. By generating radioresistant medulloblastoma cell lines, we uncovered an increased integrin-αvβ3 expression, which correlated with increased susceptibility to pharmacologic integrin-αvβ3 inhibition with cilengitide, a competitive ligand mimetic. Finally, we conducted single-photon emission computed tomography (SPECT)/MRI studies on orthotopic models using a radiolabeled integrin-αvβ3 ligand (99mTc-RAFT-RGD). This innovative approach presents the potential for a novel predictive imaging technique in the realm of medulloblastoma. Altogether, our findings lay the foundation for employing SPECT/MRI to identify a specific subset of patients with medulloblastoma eligible for integrin-αvβ3–directed therapies. This breakthrough offers a pathway toward more targeted and effective interventions in the treatment of medulloblastoma.Significance:This study demonstrates integrin-αvβ3’s fundamental role in medulloblastoma tumorigenicity and radioresistance and the effect of its expression on cilengitide functional activity.